STAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)

Reuters

08/07

STAAR Surgical Reports 55% Drop in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)

STAAR Surgical Company (NASDAQ: STAA) has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by Alcon Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806269062) on August 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557304708"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557304708\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557304708?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557304708","market":"us","top_or_hot":-1,"title":"STAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      STAAR Surgical Reports 55% Drop in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical Company</a> (NASDAQ: STAA) has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by <a href=\"https://laohu8.com/S/ALC\">Alcon Inc</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806269062) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 04:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      STAAR Surgical Reports 55% Drop in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical Company</a> (NASDAQ: STAA) has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by <a href=\"https://laohu8.com/S/ALC\">Alcon Inc</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806269062) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL8cg5bY:1","article_id":"2557304708","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557304708","pubTimestamp":1754510562,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"STAAR Surgical Company  has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer Lenses  for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by Alcon Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company"},"translate_title":"STAAR Surgical报告2025年第二季度净销售额下降55%，净亏损1680万美元，每股收益降至(0.34)美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":0.9},"content_text":"STAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)\n    \n\nSTAAR Surgical Company (NASDAQ: STAA) has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by Alcon Inc.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806269062) on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}